Research Update: Airvana Network Solutions Inc. Ratings Withdrawn Following Debt Repayment Jan 13

  • ID: 2383491
  • January 2013
  • Standard & Poors
1 of 3

On Jan. 24, 2013, Standard & Poor's Ratings Services withdrew its 'CCC-' corporate credit rating on Chelmsford, Mass.-based Airvana Network Solutions Inc. at the request of the company. As of Jan. 23, 2013, all debt had been repaid, and the rated credit facility was terminated. As a result the issue level rating is also withdrawn. Temporary number contact numbers: Molly Toll-Reed (917-685-3188); Phil Schrank (516-503-1164) Not Rated Action To From Airvana Network Solutions Inc. Corporate Credit Rating NR/-- CCC-/Negative/-- Senior Secured NR CCC- Recovery Rating NR 4...

Companies mentioned in this report are:
- Airvana Network Solutions Inc.

Action: Withdrawn

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Product Type: Research Update
Research updates complement media releases. They offer more depth and detail than summary analyses by incorporating all information published in the media release. They are more up to date than summaries in that they are published simultaneously with media releases.

Note: Product cover images may vary from those shown
2 of 3

- Airvana Network Solutions Inc.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.